The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
New research from the NIH reveals how semaglutide signaling in the brain affects weight loss plateaus, offering hope for improved efficacy and dosing strategies.
Discover how natural peptides are challenging the pharmaceutical industry, offering a new paradigm for healing, metabolic health, and cognitive enhancement amidst evolving regulatory landscapes.
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
The competition between Eli Lilly and Novo Nordisk is reshaping obesity treatment. Learn the clinical differences between Mounjaro and Wegovy, and why international market dynamics matter for patient access.
The European Medicines Agency has recommended approval for oral Wegovy, marking a significant shift in obesity treatment. Explore the implications for patients, efficacy data, and future access.
Prescriptions for weight loss drugs have tripled since 2020. Discover the science, social impact, and practical tips for navigating the GLP-1 era safely.
